ATE257707T1 - Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen - Google Patents
Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzenInfo
- Publication number
- ATE257707T1 ATE257707T1 AT98944111T AT98944111T ATE257707T1 AT E257707 T1 ATE257707 T1 AT E257707T1 AT 98944111 T AT98944111 T AT 98944111T AT 98944111 T AT98944111 T AT 98944111T AT E257707 T1 ATE257707 T1 AT E257707T1
- Authority
- AT
- Austria
- Prior art keywords
- primary headache
- antagonists
- treat primary
- single bond
- lower alkyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 206010019233 Headaches Diseases 0.000 title 1
- 231100000869 headache Toxicity 0.000 title 1
- 229940127293 prostanoid Drugs 0.000 title 1
- 150000003814 prostanoids Chemical class 0.000 title 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000018238 Primary Headache disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2807—Headache; Migraine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- External Artificial Organs (AREA)
- Slide Fasteners, Snap Fasteners, And Hook Fasteners (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9720270.9A GB9720270D0 (en) | 1997-09-25 | 1997-09-25 | Medicaments for the treatment of migraine |
| PCT/GB1998/002895 WO2000018405A1 (en) | 1997-09-25 | 1998-09-25 | Use of prostanoid antagonists for the treatment of primary headache disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257707T1 true ATE257707T1 (de) | 2004-01-15 |
Family
ID=26312305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98944111T ATE257707T1 (de) | 1997-09-25 | 1998-09-25 | Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8513027B2 (de) |
| EP (1) | EP1115404B1 (de) |
| JP (1) | JP2002525327A (de) |
| AT (1) | ATE257707T1 (de) |
| AU (1) | AU757265B2 (de) |
| CA (1) | CA2345248C (de) |
| DE (1) | DE69821142T2 (de) |
| DK (1) | DK1115404T3 (de) |
| ES (1) | ES2213914T3 (de) |
| GB (2) | GB9720270D0 (de) |
| PT (1) | PT1115404E (de) |
| WO (1) | WO2000018405A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| ATE395058T1 (de) * | 2000-03-24 | 2008-05-15 | Asterand Uk Ltd | Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten |
| DE60222168T2 (de) * | 2001-10-31 | 2008-05-15 | Medical Research Council | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie |
| PL372393A1 (en) * | 2002-02-26 | 2005-07-25 | Ortho-Mcneil Pharmaceutical Inc. | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP2015522528A (ja) | 2012-05-09 | 2015-08-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 慢性閉塞性肺疾患の予防または治療方法および医薬組成物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2028805B (en) | 1978-07-11 | 1982-11-03 | Glaxo Group Ltd | Prostanoid compounds |
| IL62734A (en) * | 1980-04-30 | 1985-10-31 | Glaxo Group Ltd | Aminocyclopentane alkenoic acids and esters,their preparation and pharmaceutical formulations |
| US4839384A (en) * | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
| JP3222891B2 (ja) | 1991-05-03 | 2001-10-29 | ジー．ディー．サール アンド カンパニー | 置換ベンゾオキサゼピン化合物、医薬品組成物およびその使用方法 |
| US5182272A (en) | 1991-05-03 | 1993-01-26 | G. D. Searle & Co. | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain |
| US5212169A (en) | 1991-10-31 | 1993-05-18 | G. D. Searle & Co. | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain |
| EP0613472A1 (de) | 1991-11-05 | 1994-09-07 | G.D. Searle & Co. | 10-acyl-dibenz(b,f)(1,4)-oxazepine und ihre thiazepine analoge verwendbar als prostaglandinantagonisten |
| WO1993013082A1 (en) | 1991-12-20 | 1993-07-08 | G.D. Searle & Co. | Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists |
| US5266571A (en) * | 1992-01-09 | 1993-11-30 | Amer Moh Samir | Treatment of hemorrhoids with 5-HT2 antagonists |
| US5395932A (en) | 1993-04-30 | 1995-03-07 | G. D. Searle & Co. | 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
| US5488046A (en) | 1993-11-03 | 1996-01-30 | G. D. Searle & Co. | Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| CA2179399A1 (en) | 1993-12-20 | 1995-06-29 | Kiyoshi Taniguchi | 4,5-diaryloxazole derivatives |
| RU2155188C2 (ru) | 1994-03-10 | 2000-08-27 | Фудзисава Фармасьютикал Со., Лтд. | Производные нафталина, фармацевтическая композиция |
| TW401408B (en) | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| AUPO713297A0 (en) | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| US20030158240A1 (en) * | 1998-09-25 | 2003-08-21 | Pharmagene Laboratories Limited | Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment |
| GB9720270D0 (en) | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| EP1071648A2 (de) | 1998-03-13 | 2001-01-31 | Merck Frosst Canada & Co. | CARBONSÄUREN UND ACYLSULFONAMIDE, SOLCHE VERBINDUNGEN ENTHALTENDE Gemenge UND BEHANDLUNGSVERFAHREN |
| CA2346038A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
| JP2003506404A (ja) | 1999-08-10 | 2003-02-18 | グラクソ グループ リミテッド | 治療、とりわけ神経障害性疼痛および結腸癌の治療におけるｅｐ４受容体リガンドの使用 |
| WO2005105147A2 (en) | 2004-05-03 | 2005-11-10 | Astellas Pharma Inc. | Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
-
1997
- 1997-09-25 GB GBGB9720270.9A patent/GB9720270D0/en not_active Ceased
-
1998
- 1998-09-25 AU AU91776/98A patent/AU757265B2/en not_active Ceased
- 1998-09-25 CA CA002345248A patent/CA2345248C/en not_active Expired - Fee Related
- 1998-09-25 WO PCT/GB1998/002895 patent/WO2000018405A1/en not_active Ceased
- 1998-09-25 AT AT98944111T patent/ATE257707T1/de active
- 1998-09-25 JP JP2000571923A patent/JP2002525327A/ja active Pending
- 1998-09-25 PT PT98944111T patent/PT1115404E/pt unknown
- 1998-09-25 EP EP98944111A patent/EP1115404B1/de not_active Expired - Lifetime
- 1998-09-25 GB GB9820936A patent/GB2341799B/en not_active Expired - Fee Related
- 1998-09-25 ES ES98944111T patent/ES2213914T3/es not_active Expired - Lifetime
- 1998-09-25 DK DK98944111T patent/DK1115404T3/da active
- 1998-09-25 DE DE69821142T patent/DE69821142T2/de not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/976,945 patent/US8513027B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU757265B2 (en) | 2003-02-13 |
| AU9177698A (en) | 2000-04-17 |
| WO2000018405A1 (en) | 2000-04-06 |
| PT1115404E (pt) | 2004-05-31 |
| GB9820936D0 (en) | 1998-11-18 |
| CA2345248A1 (en) | 2000-04-06 |
| US20080247954A1 (en) | 2008-10-09 |
| GB2341799B (en) | 2000-08-16 |
| ES2213914T3 (es) | 2004-09-01 |
| CA2345248C (en) | 2008-03-18 |
| DE69821142D1 (de) | 2004-02-19 |
| EP1115404B1 (de) | 2004-01-14 |
| EP1115404A1 (de) | 2001-07-18 |
| GB2341799A (en) | 2000-03-29 |
| US8513027B2 (en) | 2013-08-20 |
| JP2002525327A (ja) | 2002-08-13 |
| GB9720270D0 (en) | 1997-11-26 |
| DK1115404T3 (da) | 2004-04-13 |
| DE69821142T2 (de) | 2004-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3029758T3 (en) | N-acylated tricyclic azaheterorings useful as vasopressin antagonists. | |
| TW200505903A (en) | CGRP receptor antagonists | |
| DE69400824D1 (de) | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne | |
| EA199900693A1 (ru) | Атропизомеры 3-арил-4(3h)-хиназолинонов и их использование в качестве антагонистов амра-рецепторов | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| BG101806A (bg) | Индолови производни като антагонисти на 5-нт рецептори | |
| WO2005013894A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| DK0772603T3 (da) | Substituerede pyrimidinforbindelser og deres anvendelse | |
| ATE404538T1 (de) | Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität | |
| ATE275545T1 (de) | Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d | |
| ATE395058T1 (de) | Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten | |
| EA200600860A1 (ru) | Производные n-тиазол-2-илбензамида | |
| ATE257707T1 (de) | Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
| DE69819742D1 (de) | Indolderivate als 5-ht1b und 5-ht1d agonisten | |
| EA200200727A1 (ru) | Новые производные индола | |
| ATE119532T1 (de) | 7-oxabicycloheptyl-substituierte, heterocyclische amid-prostaglandin-analoge, verwendbar bei der behandlung von vasospastischen und thrombotischen krankheiten. | |
| DE60221420D1 (de) | Trennung von regioisomeren von metallphthalocyaninen | |
| SE9901237D0 (sv) | Novel use | |
| ATE227718T1 (de) | N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1115404 Country of ref document: EP |